Literature DB >> 8761438

Sulindac suppresses tumorigenesis in the Min mouse.

Y Beazer-Barclay1, D B Levy, A R Moser, W F Dove, S R Hamilton, B Vogelstein, K W Kinzler.   

Abstract

The Min mouse provides a genetically defined model for inherited and sporadic forms of human colorectal tumorigenesis. To test the suitability of this model for the evaluation and optimization of chemopreventive agents, we examined the effects of sulindac on tumorigenesis in Min mice as this compound can inhibit colorectal tumorigenesis in human familial adenomatous polyposis patients. Treatment of Min mice with sulindac in their drinking water (84 mg/l) or diet (167 and 334 p.p.m.) resulted in a significantly decreased average tumor load. The conservation of sulindac activity in the Min mouse provides an opportunity to explore the mechanism of sulindac suppression as well as to test other potential chemopreventive agents.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8761438     DOI: 10.1093/carcin/17.8.1757

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  52 in total

1.  Sulindac sulfide, but not sulindac sulfone, inhibits colorectal cancer growth.

Authors:  C S Williams; A P Goldman; H Sheng; J D Morrow; R N DuBois
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

2.  Occult progression by Apc-deficient intestinal crypts as a target for chemoprevention.

Authors:  Jared M Fischer; Arnout G Schepers; Hans Clevers; Darryl Shibata; R Michael Liskay
Journal:  Carcinogenesis       Date:  2013-08-29       Impact factor: 4.944

3.  Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling.

Authors:  Nan Li; Yaguang Xi; Heather N Tinsley; Evrim Gurpinar; Bernard D Gary; Bing Zhu; Yonghe Li; Xi Chen; Adam B Keeton; Ashraf H Abadi; Mary P Moyer; William E Grizzle; Wen-Chi Chang; Margie L Clapper; Gary A Piazza
Journal:  Mol Cancer Ther       Date:  2013-06-26       Impact factor: 6.261

4.  Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis.

Authors:  Wei Qiu; Xinwei Wang; Brian Leibowitz; Hongtao Liu; Nick Barker; Hitoshi Okada; Naohide Oue; Wataru Yasui; Hans Clevers; Robert E Schoen; Jian Yu; Lin Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

5.  Homeobox protein CDX2 reduces Cox-2 transcription by inactivating the DNA-binding capacity of nuclear factor-kappaB.

Authors:  Hiroyuki Mutoh; Hiroko Hayakawa; Hirotsugu Sakamoto; Kentaro Sugano
Journal:  J Gastroenterol       Date:  2007-09-25       Impact factor: 7.527

6.  Identification of specific genes and pathways involved in NSAIDs-induced apoptosis of human colon cancer cells.

Authors:  Richard-H Huang; Jianyuan Chai; Andrzej-S Tarnawski
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

7.  Dietary putrescine reduces the intestinal anticarcinogenic activity of sulindac in a murine model of familial adenomatous polyposis.

Authors:  Natalia A Ignatenko; David G Besselsen; Upal K Basu Roy; David E Stringer; Karen A Blohm-Mangone; Jose L Padilla-Torres; Jose M Guillen-R; Eugene W Gerner
Journal:  Nutr Cancer       Date:  2006       Impact factor: 2.900

Review 8.  Stem cell models for genetically predisposed colon cancer.

Authors:  Nitin Telang
Journal:  Oncol Lett       Date:  2020-08-20       Impact factor: 2.967

9.  Loss of GDF-15 abolishes sulindac chemoprevention in the ApcMin/+ mouse model of intestinal cancer.

Authors:  Teresa A Zimmers; Juan C Gutierrez; Leonidas G Koniaris
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-27       Impact factor: 4.553

10.  Cooperative effects of matrix metalloproteinase and cyclooxygenase-2 inhibition on intestinal adenoma reduction.

Authors:  R A Wagenaar-Miller; G Hanley; R Shattuck-Brandt; R N DuBois; R L Bell; L M Matrisian; D W Morgan
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.